{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:52Z","timestamp":1791665992577,"version":"4.3.4"},"reference-count":51,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"Importance<\/jats:title>The incidence of brain metastasis is increasing in patients with metastatic breast cancer. Treatments to extend the control of brain metastasis are urgently required.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate whether the addition of an induction treatment of bevacizumab, etoposide, and cisplatin (BEEP) improves brain-specific progression-free survival (PFS) after whole-brain radiotherapy (WBRT).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This open-label, randomized, multicenter clinical trial assessed patients with brain metastases from breast cancer (BMBC) in Taiwan from September 9, 2014, to December 24, 2018, with survival follow-up until December 31, 2021. Key inclusion criteria included metastatic brain tumors not suitable for focal treatment, WBRT naivety, age 20 to 75 years, and at least 1 measurable brain metastatic lesion. The primary end point was brain-specific PFS, with an expected hazard ratio of 0.60, a 2-sided \u03b1\u2009\u2264\u2009.20, and power of 0.8.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Eligible patients were randomly assigned at a ratio of 2:1 to the experimental arm, which involved 3 cycles of BEEP followed by WBRT, or the control arm, which involved WBRT alone.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was the determination of brain-specific PFS by local investigators according to the Response Evaluation Criteria in Solid Tumors, version 1.1, the initiation of other brain-directed treatment after WBRT, or death. Other key end points included brain-specific objective response rate after 8 weeks of BEEP treatment or WBRT and 8-month brain-specific PFS rate, PFS, and overall survival.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 118 patients with BMBC were randomized, with the intention-to-treat cohort comprising 112 patients. The median age was 56 years (range, 34-71 years), and 61 patients (54.5%) had ERBB2 (formerly HER2 or HER2\/neu)-positive disease. The median (range) brain-specific PFS was 8.1 (0.3-29.5) vs 6.5 (0.9-25.5) months in the experimental and control arms, respectively (hazard ratio, 0.71; 95% CI, 0.44-1.13; P<\/jats:italic>\u2009=\u2009.15; significant at predefined \u03b1\u2009\u2264\u2009.20). The brain-specific objective response rate at 2 months was not significantly different (BEEP treatment vs WBRT, 41.9% vs 52.6%), but the 8-month brain-specific PFS rate was significantly higher in the experimental group (48.7% vs 26.3%; P<\/jats:italic>\u2009=\u2009.03). Adverse events were generally manageable with prophylactic granulocyte colony-stimulating factor treatment.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings show that induction BEEP before WBRT may improve the control of BMBC compared with using upfront WBRT, which could address an unmet need for an effective systemic treatment for intractable brain and extracranial metastases from metastatic breast cancer.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02185352<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.5456","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T16:01:01Z","timestamp":1703174461000},"page":"325","source":"Crossref","is-referenced-by-count":27,"title":["Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer"],"prefix":"10.1001","volume":"10","author":[{"given":"Tom Wei-Wu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan"},{"name":"Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shen","family":"Dai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ming","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Surgery and Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Cheh","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University Medical College, Linkou Branch, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Yi","family":"Chao","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Chung","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Oncology and Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ching","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Surgery, MacKay Memorial Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Fang","family":"Chiu","sequence":"additional","affiliation":[{"name":"Cancer Center and Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hung","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology and Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Fang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwan-Ying","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyh-Cherng","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Ming","family":"Rau","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, E-Da Cancer Hospital and School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Yu","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Che","family":"Shen","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University Medical College, Linkou Branch, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Min","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan"},{"name":"Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Shen","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan"},{"name":"Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"coi230075r1","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer.","volume":"22","author":"Lin","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi230075r2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10549-007-9806-2","article-title":"Brain metastases in breast cancer: prognostic factors and management.","volume":"111","author":"Lee","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"coi230075r3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1517\/14656561003702412","article-title":"Systemic treatment in breast-cancer patients with brain metastasis.","volume":"11","author":"Arslan","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"23","key":"coi230075r4","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"coi230075r5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0027-9684(15)31298-0","article-title":"Characteristics of breast cancer patients with central nervous system metastases: a single-center experience.","volume":"100","author":"Harputluoglu","year":"2008","journal-title":"J Natl Med Assoc"},{"issue":"2","key":"coi230075r6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089389","article-title":"Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients.","volume":"9","author":"Hung","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"coi230075r7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nrclinonc.2010.119","article-title":"Whole-brain radiation therapy in breast cancer patients with brain metastases.","volume":"7","author":"Chargari","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"coi230075r8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.","volume":"121","author":"Darlix","year":"2019","journal-title":"Br J Cancer"},{"issue":"8","key":"coi230075r9","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/1078-0432.CCR-14-2075","article-title":"Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy.","volume":"21","author":"Lu","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"coi230075r10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi230075r11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0360-3016(97)00154-5","article-title":"Tumor-related prognostic factors for remission of brain metastases after radiotherapy.","volume":"39","author":"Nieder","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"coi230075r13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi230075r15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"28","key":"coi230075r16","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials.","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J Clin Oncol"},{"key":"coi230075r17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12885-015-1290-1","article-title":"A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis.","volume":"15","author":"Wu","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"coi230075r18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11060-020-03510-y","article-title":"Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival.","volume":"148","author":"Chen","year":"2020","journal-title":"J Neurooncol"},{"issue":"9","key":"coi230075r19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"issue":"3","key":"coi230075r20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006486","article-title":"Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.","volume":"2","author":"Goel","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"coi230075r21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/2042098611430109","article-title":"Risks and benefits with bevacizumab: evidence and clinical implications.","volume":"3","author":"Kurkjian","year":"2012","journal-title":"Ther Adv Drug Saf"},{"issue":"12","key":"coi230075r22","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","article-title":"Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.","volume":"7","author":"Ma","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"coi230075r23","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","article-title":"Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors.","volume":"64","author":"Tong","year":"2004","journal-title":"Cancer Res"},{"issue":"32","key":"coi230075r24","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","article-title":"RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi230075r25","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1634\/theoncologist.2012-0043","article-title":"Targeting angiogenesis in metastatic breast cancer.","volume":"17","author":"Reddy","year":"2012","journal-title":"Oncologist"},{"issue":"7","key":"coi230075r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18475","article-title":"Effect of bevacizumab in combination with standard oxaliplatin-based regimens in patients with metastatic colorectal cancer: a randomized clinical trial.","volume":"4","author":"Avallone","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"15","key":"coi230075r27","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1200\/jco.2014.32.15_suppl.1076","article-title":"Does chemotherapy schedule matter when combining with bevacizumab? a stratified meta-analysis of randomized controlled trials.","volume":"32","author":"Chang","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"coi230075r28","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.1158\/0008-5472.CAN-13-1989","article-title":"Benefits of vascular normalization are dose and time dependent\u2013letter.","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"coi230075r29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1186\/s12885-016-2494-8","article-title":"A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"coi230075r30","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"issue":"1","key":"coi230075r31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"issue":"13","key":"coi230075r32","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","article-title":"Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.","volume":"13","author":"Dickson","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"14","key":"coi230075r33","doi-asserted-by":"publisher","first-page":"23087","DOI":"10.18632\/oncotarget.v8i14","article-title":"Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.","volume":"8","author":"Mollard","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"coi230075r34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/psp4.v7.1","article-title":"Revisiting bevacizumab?+?cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma.","volume":"7","author":"Imbs","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"30","key":"coi230075r35","doi-asserted-by":"publisher","first-page":"30394","DOI":"10.18632\/oncotarget.v6i30","article-title":"Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the BRANCH trial.","volume":"6","author":"Avallone","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"coi230075r36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13058-020-01372-w","article-title":"Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.","volume":"22","author":"Leone","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"6","key":"coi230075r37","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","article-title":"Brain metastases: the HER2 paradigm.","volume":"13","author":"Lin","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"coi230075r38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1200\/JCO.2010.33.3294","article-title":"The dandelion effect: treat the whole lawn or weed selectively?","volume":"29","author":"Mehta","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi230075r39","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/0284186X.2017.1418534","article-title":"Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014.","volume":"57","author":"Jeene","year":"2018","journal-title":"Acta Oncol"},{"issue":"3","key":"coi230075r40","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S0360-3016(02)02967-X","article-title":"Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study.","volume":"54","author":"Mahmoud-Ahmed","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"coi230075r41","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s10549-017-4466-3","article-title":"Survival and level of care among breast cancer patients with brain metastases treated with whole brain radiotherapy.","volume":"166","author":"Frisk","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"coi230075r42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4048\/jbc.2015.18.1.29","article-title":"Local control of brain metastasis: treatment outcome of focal brain treatments in relation to subtypes.","volume":"18","author":"Chong","year":"2015","journal-title":"J Breast Cancer"},{"issue":"1","key":"coi230075r43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/annonc\/mdu488","article-title":"Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.","volume":"26","author":"Cao","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"coi230075r44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3-4","key":"coi230075r45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/07357909009012049","article-title":"Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.","volume":"8","author":"Cocconi","year":"1990","journal-title":"Cancer Invest"},{"issue":"7","key":"coi230075r46","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#","article-title":"Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.","volume":"85","author":"Franciosi","year":"1999","journal-title":"Cancer"},{"issue":"3","key":"coi230075r47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdq434","article-title":"Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.","volume":"22","author":"Metro","year":"2011","journal-title":"Ann Oncol"},{"issue":"6","key":"coi230075r48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2011.58","article-title":"The biology of brain metastases-translation to new therapies.","volume":"8","author":"Eichler","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"35","key":"coi230075r49","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1200\/JCO.2009.23.7545","article-title":"Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.","volume":"27","author":"Horn","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi230075r50","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi230075r51","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"coi230075r12","unstructured":"Snow? G. Randomization for block random clinical trials: R package \u2018blockrand\u2019. Comprehensive R Archive Network: 2020. Accessed August 27, 2021. https:\/\/CRAN.R-project.org\/package=blockrand"},{"key":"coi230075r14","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. National Cancer Institute: 2010. Accessed June 14, 2010. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2813225\/jamaoncology_chen_2023_oi_230075_1710962810.24274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T15:04:41Z","timestamp":1711033481000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2813225"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.5456","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}